Study of WSD0922-FU for advanced lung cancer with C797S mutation
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug, WSD0922-FU, for people with advanced non-small cell lung cancer that has a specific genetic change called C797S. It is for those whose cancer has gotten worse after treatment with osimertinib.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer that cannot be cured with surgery or radiation.
- Your cancer has a specific genetic change called C797S in the EGFR gene.
- Your cancer has gotten worse while you were taking osimertinib as your first treatment.
- You are 18 years or older and able to care for yourself (ECOG score 0 or 1).
- You have at least one tumor that has not been treated with radiation and can be measured.
- You are not pregnant, not able to become pregnant, and not planning to father a child.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two oral targeted drugs for people with advanced non-small cell lung cancer that has an EGFR mutation. It may help if you have already been treated with a third-generation EGFR pill or if you are starting treatment for the first time.
This trial tests a new combination of two drugs (BL-B01D1 and osimertinib) versus osimertinib alone as the first treatment for people with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination works better at stopping the cancer from growing.
This trial tests a combination of two targeted drugs (DZD9008 and AZD4205) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests whether adding SYS6010 to osimertinib before surgery works better than osimertinib alone for people with a type of lung cancer that has an EGFR mutation. The goal is to shrink the tumor and improve surgery outcomes.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This trial tests an oral drug called DZD6008 for people with advanced non-small cell lung cancer (NSCLC) that has certain EGFR mutations. It may be an option for those who have tried other EGFR treatments or are new to treatment.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.